On October 31, 2025, Bavarian Nordic A/S, a biotechnology leader specializing in vaccines, announced the award of an expanded procurement framework contract from the European Commission's Health Emergency Preparedness and Response Authority (HERA). This new contract authorizes the purchase of up to 8 million doses of the company’s MVA-BN® smallpox/mpox vaccine over the next four years, representing a significant increase compared to previous agreements and a major milestone for public health preparedness across Europe.

The framework contract replaces the previous procurement arrangement established in 2022 and now brings together 20 EU member states, along with several other European countries, under a unified purchasing agreement. The decision to scale up the contract demonstrates Europe’s increased commitment to proactive infectious disease risk management, especially amid ongoing concerns about emerging or re-emerging viral threats such as smallpox and mpox (monkeypox).

Paul Chaplin, President and CEO of Bavarian Nordic, emphasized the critical nature of regional supply security, stating: “We are pleased to extend our collaboration with HERA to facilitate broad access to our smallpox and mpox vaccine across the region. This agreement is a recognition of public health security as part of the resilience that the EU is building to unify against threats on a larger scale, and we are proud to be part of the endeavors to safeguard Europe’s citizens against life-threatening diseases.”

Under the terms of the expanded framework, approximately 1.1 million doses have already been committed, with the first 750,000 doses expected to be supplied in 2026. The contract structure also allows for supply at adjusted pricing for vaccine donations to low- and lower-middle-income countries, ensuring that the European stockpile can contribute to global responses to outbreaks as needed. Final signature of the contract is pending completion of a 10-day standstill period to comply with EU procurement regulations.

From a B2B and operational standpoint, this procurement framework ensures continued production and distribution stability within the European pharmaceutical supply chain. It also demonstrates strong alignment between manufacturing partners, supply chain logistics operators, national authorities, and supranational agencies, reinforcing Europe’s position as a coordinated marketplace for medical countermeasures. For pharmaceutical executives, procurement managers, and logistics leaders, this signals both substantial supply commitments and greater predictability of demand, supporting investment and capacity planning throughout the vaccine manufacturing and distribution value chain.

The vaccine (MVA-BN) is a non-replicating, third-generation smallpox and mpox vaccine approved by major regulators globally (marketed under the names JYNNEOS, IMVAMUNE, and IMVANEX in different territories). Originally developed in partnership with the U.S. government to ensure safe smallpox vaccination for immunocompromised populations, the vaccine now holds a critical dual indication amid growing mpox concerns. Recent outbreaks have underscored the urgency of access to such vaccines, prompting Europe and other regions to invest in larger, more flexible stockpiles.

In addition to fortifying European preparedness against high-consequence viral diseases, this procurement deal offers B2B opportunities for contract manufacturing organizations (CMOs), cold chain logistics specialists, and packaging providers, who will be central to the successful rollout and storage of these vaccine quantities. Moreover, the framework’s flexibility to respond to public health emergencies demonstrates regulatory agility, supporting not just routine preparedness but also accelerated access and distribution under crisis scenarios.

For companies engaged in analytical equipment, cold chain storage, packaging machinery, distribution solutions, and regional supply chain consulting, the Bavarian Nordic-EU framework exemplifies the scale and strategic nature of Europe’s current investments in public health infrastructure. The enhanced contract further consolidates Bavarian Nordic’s position as a preferred partner for governments and agencies managing vaccine stockpiles. As of today, this marks one of Europe's most substantial pan-regional, B2B vaccine procurement arrangements of 2025, with far-reaching implications for manufacturing, supply assurance, and regional resilience.